CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Guidelinehttps://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa575/5898842

JOURNAL:Eur Heart J. Article Link

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

J-P Collet, H Thiele, E Barbato et al. Keywords: ACS without persistent ST-segment elevation; Guidelines; acute cardiac care; angioplasty; anticoagulation; antiplatelet; apixaban; aspirin; atherothrombosis; betablockers; bleedings; bivalirudin; CABG; cangrelor; chest pain unit; clopidogrel; dabigatran; diabetes; DAPT; early invasive strategy; edoxaban; enoxaparin; fondaparinux; glycoprotein IIb/IIIa inhibitors; heparin; high-sensitivity troponin; MINOCA; myocardial ischaemia; MI; nitrates; platelet inhibition; prasugrel; revascularization; rhythm monitoring; rivaroxaban; stent; ticagrelor; triple therapy; unstable angina

Full Text PDF